Cargando…

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965

Detalles Bibliográficos
Autores principales:	McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156454/ https://www.ncbi.nlm.nih.gov/pubmed/32203218 http://dx.doi.org/10.1038/s41416-020-0801-2

Ejemplares similares

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
por: McNeillis, Rosie, et al.
Publicado: (2020)

In Vivo Anticancer Activity of AZD3965: A Systematic Review
por: Silva, Ana, et al.
Publicado: (2021)

Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
por: Braga, Marta, et al.
Publicado: (2020)

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma
por: Noble, Richard A., et al.
Publicado: (2017)

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
por: Beloueche-Babari, Mounia, et al.
Publicado: (2020)

In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
por: Benyahia, Zohra, et al.
Publicado: (2021)

Pyruvate carboxylase deficiency: An underestimated cause of lactic acidosis
por: Habarou, F., et al.
Publicado: (2014)

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
por: Curtis, Nicola J., et al.
Publicado: (2017)

Citrate anticoagulation for continuous venovenous haemodiafiltration: the impact of a novel protocol on patients receiving therapy in one regional hospital
por: Highgate, J, et al.
Publicado: (2015)

The LXR ligand GW3965 inhibits Newcastle disease virus infection by affecting cholesterol homeostasis
por: Sheng, Xiang-xiang, et al.
Publicado: (2016)

Differences in polysomnographic, nocturnal penile tumescence and penile doppler ultrasound findings in men with stuttering priapism and sleep-related painful erections
por: Johnson, Mark, et al.
Publicado: (2021)

A Rare Case of Type B Neonatal Pyruvate Carboxylase Enzyme Deficiency Presenting With Refractory Lactic Acidosis in the Early Neonatal Period
por: Sharif, Saima, et al.
Publicado: (2022)

Pyruvate carboxylase and cancer progression
por: Kiesel, Violet A., et al.
Publicado: (2021)

Structure of the acetophenone carboxylase core complex: prototype of a new class of ATP-dependent carboxylases/hydrolases
por: Weidenweber, Sina, et al.
Publicado: (2017)

Acetyl-CoA Carboxylases and Diseases
por: Wang, Yu, et al.
Publicado: (2022)

The Liver X Receptor Agonist GW3965 Improves Recovery from Mild Repetitive Traumatic Brain Injury in Mice Partly through Apolipoprotein E
por: Namjoshi, Dhananjay R., et al.
Publicado: (2013)

Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells
por: Barnes, Emily M. E., et al.
Publicado: (2020)

Expression Profiles of Phosphoenolpyruvate Carboxylase and Phosphoenolpyruvate Carboxylase Kinase Genes in Phalaenopsis, Implications for Regulating the Performance of Crassulacean Acid Metabolism
por: Ping, Chia-Yun, et al.
Publicado: (2018)

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)

Early evolution of the biotin-dependent carboxylase family
por: Lombard, Jonathan, et al.
Publicado: (2011)

Chemical Genetics of Acetyl-CoA Carboxylases
por: Zu, Xuyu, et al.
Publicado: (2013)

A Unique Case of Pyruvate Carboxylase Deficiency
por: Hidalgo, Jessica, et al.
Publicado: (2021)

Molecular evolution of urea amidolyase and urea carboxylase in fungi
por: Strope, Pooja K, et al.
Publicado: (2011)

Correction: Early evolution of the biotin-dependent carboxylase family
por: Lombard, Jonathan, et al.
Publicado: (2012)

The dynamic organization of fungal acetyl-CoA carboxylase
por: Hunkeler, Moritz, et al.
Publicado: (2016)

Oligomerization and characteristics of phosphoenolpyruvate carboxylase in Synechococcus PCC 7002
por: Durall, Claudia, et al.
Publicado: (2020)

Conservation and Divergence of Phosphoenolpyruvate Carboxylase Gene Family in Cotton
por: Wei, Yangyang, et al.
Publicado: (2022)

Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines
por: Wang, Qingbo, et al.
Publicado: (2019)

Ultrasensitive regulation of anapleurosis via allosteric activation of PEP carboxylase
por: Xu, Yi-Fan, et al.
Publicado: (2012)

Multiple Carboxylase Deficiency (Late Onset) Due to Deficiency of Biotinidase
por: Mukhopadhyay, Debadatta, et al.
Publicado: (2014)

Mechanisms of Inhibition of Rhizobium etli Pyruvate Carboxylase by l-Aspartate
por: Sirithanakorn, Chaiyos, et al.
Publicado: (2014)

A distinct holoenzyme organization for two-subunit pyruvate carboxylase
por: Choi, Philip H., et al.
Publicado: (2016)

Allosteric regulation alters carrier domain translocation in pyruvate carboxylase
por: Liu, Yumeng, et al.
Publicado: (2018)

Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2018)

Dynamics of the Degradation of Acetyl-CoA Carboxylase Herbicides in Vegetables
por: Jursík, Miroslav, et al.
Publicado: (2021)

Fibroblast pyruvate carboxylase is required for collagen production in the tumor microenvironment
por: Schwörer, Simon, et al.
Publicado: (2021)

Targeting acetyl-CoA carboxylase 1 for cancer therapy
por: Yu, Yong, et al.
Publicado: (2023)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Mono
por: Wu, Cheng'en, ca. 1500-ca. 1582
Publicado: (1945)

Cannot write session to /tmp/vufind_sessions/sess_c78ha0400v9q6rh1uqk1fh23d3